Neurological diseases, including neurodegenerative and neurodevelopmental disorders, affect nearly one in six of the world’s population. The burden of the resulting deaths and disability is set to rise during the next few decades as a consequence of an aging population. To address this, zebrafish have become increasingly prominent as a model for studying human neurological diseases and exploring potential therapies. Zebrafish offer numerous benefits, such as genetic homology and brain similarities, complementing traditional mammalian models and serving as a valuable tool for genetic screening and drug discovery. In this comprehensive review, we highlight various drug delivery techniques and systems employed for therapeutic interventions of neurological diseases in zebrafish, and evaluate their suitability. We also discuss the challenges encountered during this process and present potential advancements in innovative techniques.

Dysphagia in pemphigus vulgaris (PV) patients should not be attributed solely to PV. Eosinophilic esophagitis (EoE) can coexist and requires endoscopic evaluation and biopsy for accurate diagnosis. Both conditions may share underlying immune mechanisms, emphasizing the importance of precise diagnosis and targeted treatment.

We describe a case of 72-year-old female patient diagnosed with multiple myeloma (MM) in 2023, who presented with generalized fatigue. Patient was found to have elevated liver enzymes on biochemical workup. Her hepatotoxicity was attributed to Bortezomib therapy after ruling out other etiologies. Initially, patient’s liver enzymes were normal prior to Bortezomib initiation. However, her liver enzymes started trending up at day 3 during her second session of Bortezomib. Liver function tests normalized 2 weeks after discontinuing Bortezomib. This fact points to a drug-induced liver injury (DILI) whereby Bortezomib is the likely culprit. Patient was started on thalidomide-containing regimen thereafter. Her liver enzymes remained within normal range following thalidomide-based regimen.

Managing adult‐onset Still's disease complicated by severe hepatitis requires vigilant monitoring and adaptable therapeutic strategies. Standard treatments such as tocilizumab and rituximab can cause adverse reactions or lose efficacy. The interplay of systemic inflammation and liver involvement highlights the need for ongoing research to find effective, safe treatment alternatives.

Blastocystis hominis infection in patients with Parkinson’s disease may exacerbate gut microbiota dysbiosis, potentially worsening neurological sympt

We present the case of a 39‐year‐old woman with a history of severe ulcerative colitis (UC) that was refractory to 5‐aminosalicylates, corticosteroids, and biologics, and who subsequently underwent total colectomy with ileal pouch–anal anastomosis (IPAA). She developed chronic antibiotic‐refractory pouchitis (CARP) characterized by recurrent abdominal pain, cramping, and diarrhea unresponsive to standard treatments. A comprehensive workup, including testing for anti‐tissue transglutaminase IgA antibodies, led to the diagnosis of de novo celiac disease, confirmed by endoscopic and histopathologic findings. Initiation of a gluten‐free diet resulted in the resolution of symptoms, with no relapse observed during a 9‐month follow‐up. Our case highlights the importance of considering secondary etiologies such as celiac disease in patients with chronic refractory pouchitis and emphasizes the need for tailored management strategies.